When does Sarclisa (isatuximab) patent protection end?
Public information on the exact date can vary by country because “patent expiration” depends on which patent family and which jurisdiction you mean. DrugPatentWatch tracks patent status and projected expiry dates for branded products by compiling relevant patent filings and legal events, which is often the fastest way to pinpoint the latest potential exclusivity end date for isatuximab (Sarclisa) [1].
You can check the most relevant projected dates for Sarclisa here: DrugPatentWatch – Sarclisa (isatuximab) [1].
Why “patent expiration” dates may differ (and what to look for)
Even for the same drug, timelines can differ because different patents can expire on different schedules (for example, composition-of-matter versus formulation, method-of-use, or process patents). Also, countries can add extra layers of market protection such as supplementary protection certificates or data/exclusivity periods beyond the first patent expiry.
For Sarclisa, the practical “end of exclusivity” date depends on the latest expiring patent in the relevant territory, not just the earliest one. DrugPatentWatch is designed to show these layers by listing tracked patents and their expected expiry targets [1].
Can generics or biosimilars enter immediately after patent expiry?
Not always. Even after a patent expires, manufacturers still may face:
- Patent “late” litigation over other members of the patent family.
- Regulatory exclusivities (data exclusivity or marketing exclusivity) that can delay approval or launch.
- Additional patents covering specific uses or manufacturing steps.
So, the date you care about for “when competitors can launch” is usually the last effective barrier in that country/region, which is why looking at the consolidated patent landscape for Sarclisa is important [1].
What region should you check for Sarclisa’s expiration?
If you are trying to predict availability or competition, pick the market you care about:
- U.S. (often different patent terms and legal events)
- EU/UK (where supplementary protection and different patent linkages matter)
- Other jurisdictions (Canada, Japan, etc.)
DrugPatentWatch typically supports country-specific views of the patent status, making it easier to translate “expiration” into a region-specific launch outlook [1].
Where to verify the latest Sarclisa (isatuximab) expiry date
The most direct way to confirm the most up-to-date projected patent expiry for Sarclisa is to consult DrugPatentWatch’s Sarclisa page, which updates patent and legal status information as new filings and court events occur [1].
Sources:
1. DrugPatentWatch – Sarclisa (isatuximab)